24
Views
0
CrossRef citations to date
0
Altmetric
Research Article

The value of LCI-based modified Kyoto classification risk scoring system in predicting the risk of early gastric cancer

, , , , , , , & ORCID Icon show all
Received 31 Jan 2024, Accepted 29 Mar 2024, Published online: 05 Apr 2024

References

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
  • Isobe Y, Nashimoto A, Akazawa K, et al. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer. 2011;16(1):1–27. doi:10.1007/s10120-012-0163-4.
  • Shitara K, Chin K, Yoshikawa T, et al. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer. 2017;20(1):175–181. doi:10.1007/s10120-015-0581-1.
  • Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(5):531–546. doi:10.6004/jnccn.2013.0070.
  • Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007;56(5):631–636. doi:10.1136/gut.2006.106666.
  • Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71(7):1150–1158. doi:10.1016/j.gie.2009.12.029.
  • Zhang L, Liu Y, You P, et al. Occurrence of gastric cancer in patients with atrophic gastritis during long-term follow-up. Scand J Gastroenterol. 2018;53(7):843–848. doi:10.1080/00365521.2018.1477987.
  • Rugge M, Meggio A, Pravadelli C, et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut. 2019;68(1):11–17. doi:10.1136/gutjnl-2017-314600.
  • Bellolio E, Riquelme I, Riffo-Campos AL, et al. Assessment of gastritis and gastric cancer risk in the Chilean population using the OLGA system. Pathol Oncol Res. 2019;25(3):1135–1142. doi:10.1007/s12253-018-0532-3.
  • Iwatsuka K, Gotoda T, Kusano C, et al. Clinical management of esophagogastroduodenoscopy by clinicians under the former guidelines of the Japan gastroenterological endoscopy society for patients taking anticoagulant and antiplatelet medications. Gastric Cancer. 2014;17(4):680–685. doi:10.1007/s10120-013-0333-z.
  • Uedo N, Ishihara R, Iishi H, et al. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. Endoscopy. 2006;38(8):819–824. doi:10.1055/s-2006-944632.
  • Pimentel-Nunes P, Dinis-Ribeiro M, Soares J, et al. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions. Endoscopy. 2012;44(3):236–246. doi:10.1055/s-0031-1291537.
  • Pimentel-Nunes P, Libanio D, Lage J, et al. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. Endoscopy. 2016;48(8):723–730. doi:10.1055/s-0042-108435.
  • Ono S, Kato M, Tsuda M, et al. Lavender color in linked color imaging enables noninvasive detection of gastric intestinal metaplasia. Digestion. 2018;98(4):222–230. doi:10.1159/000489454.
  • Chen H, Wang H, Wu X, et al. Predictability of gastric intestinal metaplasia by patchy lavender color seen on linked color imaging endoscopy. Lasers Med Sci. 2019;34(9):1791–1797. doi:10.1007/s10103-019-02775-8.
  • Zhang G, Zheng J, Zheng L, et al. Gastric intestinal metaplasia assessment between linked color imaging based on endoscopy and pathology. Scand J Gastroenterol. 2021;56(1):103–110. doi:10.1080/00365521.2020.1849385.
  • Zheng J, Zhang G, Gao C, et al. Linked color imaging-based endoscopic grading of gastric intestinal metaplasia and histological gastritis staging in the assessment of gastric cancer risk. Scand J Gastroenterol. 2022;57(11):1374–1380. doi:10.1080/00365521.2022.2085061.
  • Kim N. Chemoprevention of gastric cancer by Helicobacter pylori eradication and its underlying mechanism. J Gastroenterol Hepatol. 2019;34(8):1287–1295. doi:10.1111/jgh.14646.
  • Polk DB, Peek RM.Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10(6):403–414. doi:10.1038/nrc2857.
  • Abuderman AWA, Syed R, Mateen A, et al. Epidemiological characterization, genetic alterations of Helicobacter pylori infection in chronic gastric disorder and prognostic values of heterozygosity loss in chromosome 3p. Mol Biol Rep. 2019;46(4):4323–4332. doi:10.1007/s11033-019-04886-5.
  • Kamada T, Haruma K, Inoue K, et al. [Helicobacter pylori infection and endoscopic gastritis -Kyoto classification of gastritis]. Nihon Shokakibyo Gakkai zasshi = the Japanese Journal of Gastro-Enterology. 2015;112(6):982–993.
  • Sugimoto M, Ban H, Ichikawa H, et al. Efficacy of the Kyoto classification of gastritis in identifying patients at high risk for gastric cancer. Intern Med. 2017;56(6):579–586. doi:10.2169/internalmedicine.56.7775.
  • Shichijo S, Hirata Y, Niikura R, et al. Association between gastric cancer and the Kyoto classification of gastritis. J Gastroenterol Hepatol. 2017;32(9):1581–1586. doi:10.1111/jgh.13764.
  • Kawamura M, Uedo N, Koike T, et al. Kyoto classification risk scoring system and endoscopic grading of gastric intestinal metaplasia for gastric cancer: multicenter observation study in Japan. Dig Endosc. 2022;34(3):508–516. doi:10.1111/den.14114.
  • Wei N, Zhong Z, Shi R. A novel method of grading gastric intestinal metaplasia based on the combination of subtype and distribution. Cancer Cell Int. 2021;21(1):61. doi:10.1186/s12935-021-01758-6.
  • Zhao J, Xu S, Gao Y, et al. Accuracy of endoscopic diagnosis of Helicobacter pylori based on the Kyoto classification of gastritis: a multicenter study. Front Oncol. 2020;10:599218. (doi:10.3389/fonc.2020.599218.
  • Cassaro M, Rugge M, Gutierrez O, et al. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol. 2000;95(6):1431–1438. doi:10.1111/j.1572-0241.2000.02074.x.
  • Lahner E, Bordi C, Cattaruzza MS, et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther. 2005;22(5):471–481. doi:10.1111/j.1365-2036.2005.02582.x.
  • Vannella L, Lahner E, Osborn J, et al. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther. 2010;31(9):1042–1050. doi:10.1111/j.1365-2036.2010.04268.x.
  • Masuyama H, Yoshitake N, Sasai T, et al. Relationship between the degree of endoscopic atrophy of the gastric mucosa and carcinogenic risk. Digestion. 2015;91(1):30–36. doi:10.1159/000368807.
  • Song JH, Kim SG, Jin EH, et al. Risk factors for gastric tumorigenesis in underlying gastric mucosal atrophy. Gut Liver. 2017;11(5):612–619. doi:10.5009/gnl16488.
  • Quach DT, Hiyama T. Assessment of endoscopic gastric atrophy according to the Kimura-Takemoto classification and its potential application in daily practice. Clin Endosc. 2019;52(4):321–327. doi:10.5946/ce.2019.072.
  • Park YM, Kim JH, Baik SJ, et al. Clinical risk assessment for gastric cancer in asymptomatic population after a health check-up: an individualized consideration of the risk factors. Medicine. 2016;95(44):e5351. doi:10.1097/MD.0000000000005351.
  • Huang Y, Li H, Long X, et al. Lessons learned from upper gastrointestinal endoscopy in asymptomatic chinese. Helicobacter. 2021;26(3):e12803. doi:10.1111/hel.12803.
  • Simko V, Anand N, Ginter E. Gastric intestinal metaplasia – age, ethnicity and surveillance for gastric cancer. Bratisl Lek Listy. 2015;116(1):3–8. doi:10.4149/bll_2015_001.
  • Aumpan N, Vilaichone RK, Pornthisarn B, et al. Predictors for regression and progression of intestinal metaplasia (IM): a large population-based study from low prevalence area of gastric cancer (IM-predictor trial). PLoS One. 2021;16(8):e0255601. doi:10.1371/journal.pone.0255601.
  • Joo YE, Park HK, Myung DS, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia: a nationwide multicenter prospective study in Korea. Gut Liver. 2013;7(3):303–310. doi:10.5009/gnl.2013.7.3.303.
  • Huang RJ, Ende AR, Singla A, et al. Prevalence, risk factors, and surveillance patterns for gastric intestinal metaplasia among patients undergoing upper endoscopy with biopsy. Gastrointest Endosc. 2020;91(1):70–77 e71. doi:10.1016/j.gie.2019.07.038.
  • Tsukui T, Kashiwagi R, Sakane M, et al. Aging increases, and duodenal ulcer reduces the risk for intestinal metaplasia of the gastric corpus in Japanese patients with dyspepsia. J Gastroenterol Hepatol. 2001;16(1):15–21. doi:10.1046/j.1440-1746.2001.02380.x.
  • Mera RM, Bravo LE, Camargo MC, et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. 2018;67(7):1239–1246. doi:10.1136/gutjnl-2016-311685.
  • O'Connor A, Bowden A, Farrell E, et al. Risk of progression of gastric intestinal metaplasia is significantly greater when detected in both antrum and body. Dig Dis Sci. 2021;66(10):3470–3475. doi:10.1007/s10620-020-06659-8.
  • den Hollander WJ, Holster IL, den Hoed CM, et al. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. Gut. 2019;68(4):585–593. doi:10.1136/gutjnl-2017-314498.
  • Esposito G, Pimentel-Nunes P, Angeletti S, et al. Endoscopic grading of gastric intestinal metaplasia (EGGIM): a multicenter validation study. Endoscopy. 2019;51(6):515–521. doi:10.1055/a-0808-3186.
  • Kamada T, Shiotani A, Haruma K. [Nodular gastritis and gastric cancer in young adult]. Nihon Rinsho Japanese J Clin Med. 2012;70(10):1807–1811.
  • Nishibayashi H, Kanayama S, Kiyohara T, et al. Helicobacter pylori-induced enlarged-fold gastritis is associated with increased mutagenicity of gastric juice, increased oxidative DNA damage, and an increased risk of gastric carcinoma. J Gastroenterol Hepatol. 2003;18(12):1384–1391. doi:10.1046/j.1440-1746.2003.03192.x.
  • Watanabe M, Kato J, Inoue I, et al. Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis. Int J Cancer. 2012;131(11):2632–2642. doi:10.1002/ijc.27514.
  • Toyoshima O, Nishizawa T, Yoshida S, et al. Comparison of endoscopic gastritis based on Kyoto classification between diffuse and intestinal gastric cancer. World J Gastrointest Endosc. 2021;13(5):125–136. doi:10.4253/wjge.v13.i5.125.
  • Haruma K, Komoto K, Kamada T, et al. Helicobacter pylori infection is a major risk factor for gastric carcinoma in young patients. Scand J Gastroenterol. 2000;35(3):255–259.
  • Miyamoto M, Haruma K, Yoshihara M, et al. Nodular gastritis in adults is caused by Helicobacter pylori infection. Dig Dis Sci. 2003;48(5):968–975. doi:10.1023/a:1023016000096.
  • Nishikawa I, Kato J, Terasoma S, et al. Nodular gastritis in association with gastric cancer development before and after Helicobacter pylori eradication. JGH Open. 2018;2(3):80–86. doi:10.1002/jgh3.12049.
  • Shiotani A, Kamada T, Kumamoto M, et al. Nodular gastritis in japanese young adults: endoscopic and histological observations. J Gastroenterol. 2007;42(8):610–615. doi:10.1007/s00535-007-2073-5.
  • Kitamura S, Yasuda M, Muguruma N, et al. Prevalence and characteristics of nodular gastritis in japanese elderly. J Gastroenterol Hepatol. 2013;28(7):1154–1160. doi:10.1111/jgh.12180.
  • Miyamoto M, Haruma K, Yoshihara M, et al. Five cases of nodular gastritis and gastric cancer: a possible association between nodular gastritis and gastric cancer. Dig Liver Dis. 2002;34(11):819–820. doi:10.1016/s1590-8658(02)80078-0.
  • Yoshii S, Mabe K, Watano K, et al. Validity of endoscopic features for the diagnosis of Helicobacter pylori infection status based on the Kyoto classification of gastritis. Dig Endosc. 2020;32(1):74–83. doi:10.1111/den.13486.
  • Dohi O, Yagi N, Onozawa Y, et al. Linked color imaging improves endoscopic diagnosis of active Helicobacter pylori infection. Endosc Int Open. 2016;4(7):E800–805. doi:10.1055/s-0042-109049.
  • Sakae H, Kanzaki H, Satomi T, et al. Linked color imaging (LCI) emphasizes the color changes in the gastric Mucosa after Helicobacter pylori eradication. Dig Dis Sci. 2022;67(6):2375–2384. doi:10.1007/s10620-021-07030-1.
  • Nagata N, Shimbo T, Akiyama J, et al. Predictability of gastric intestinal metaplasia by mottled patchy erythema seen on endoscopy. Gastroenterology Res. 2011;4(5):203–209.
  • Watanabe K, Nagata N, Nakashima R, et al. Predictive findings for Helicobacter pylori-uninfected, -infected and -eradicated gastric mucosa: validation study. World J Gastroenterol. 2013;19(27):4374–4379. doi:10.3748/wjg.v19.i27.4374.
  • Glover B, Teare J, Ashrafian H, et al. The endoscopic predictors of Helicobacter pylori status: a meta-analysis of diagnostic performance. Ther Adv Gastrointest Endosc. 2020;13:2631774520950840. (doi:10.1177/2631774520950840.
  • Moribata K, Iguchi JK, Nakachi K, et al. Endoscopic features associated with development of metachronous gastric cancer in patients who underwent endoscopic resection followed by Helicobacter pylori eradication. Dig Endosc. 2016;28(4):434–442. doi:10.1111/den.12581.
  • Majima A, Dohi O, Takayama S, et al. Linked color imaging identifies important risk factors associated with gastric cancer after successful eradication of Helicobacter pylori. Gastrointest Endosc. 2019;90(5):763–769. doi:10.1016/j.gie.2019.06.043.
  • Ishida T, Dohi O, Yoshida N, et al. Enhanced visibility in evaluating gastric cancer and Helicobacter pylori-associated gastritis using linked color imaging with a Light-Emitting diode light source. Dig Dis Sci. 2022;67(6):2367–2374. doi:10.1007/s10620-021-07234-5.
  • Nomura S, Terao S, Adachi K, et al. Endoscopic diagnosis of gastric mucosal activity and inflammation. Dig Endosc. 2013;25(2):136–146. doi:10.1111/j.1443-1661.2012.01357.x.
  • Yuan C, Lin XM, Ou Y, et al. Gastric foveolar elongation causes invisibility of regular arrangement of collecting venules in chronic active and inactive gastritis. Helicobacter. 2021;26(1):e12770. doi:10.1111/hel.12770.
  • Garcés-Durán R, García-Rodríguez A, Córdova H, et al. Association between a regular arrangement of collecting venules and absence of Helicobacter pylori infection in a European population. Gastrointest Endosc. 2019;90(3):461–466. doi:10.1016/j.gie.2019.05.027.
  • Ashorn M, Ruuska T, Karikoski R, et al. Gastric mucosal cell densities in Helicobacter pylori-positive and -negative dyspeptic children and healthy controls. J Pediatr Gastroenterol Nutr. 1994;18(2):146–151. doi:10.1097/00005176-199402000-00005.
  • Kodama M, Murakami K, Okimoto T, et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol. 2012;47(4):394–403. doi:10.1007/s00535-011-0504-9.
  • Kanzaki H, Takenaka R, Kawahara Y, et al. Linked color imaging (LCI), a novel image-enhanced endoscopy technology, emphasizes the color of early gastric cancer. Endosc Int Open. 2017;5(10):E1005–E1013. doi:10.1055/s-0043-117881.
  • Kubo K, Kimura N, Matsuda S, et al. Linked color imaging highlights flat early gastric cancer. Case Rep Gastroenterol. 2019;13(3):532–538. doi:10.1159/000504957.
  • Ono S, Abiko S, Kato M. Linked color imaging enhances gastric cancer in gastric intestinal metaplasia. Dig Endosc. 2017;29(2):230–231. doi:10.1111/den.12757.
  • Fukuda H, Miura Y, Osawa H, et al. Linked color imaging can enhance recognition of early gastric cancer by high color contrast to surrounding gastric intestinal metaplasia. J Gastroenterol. 2019;54(5):396–406. doi:10.1007/s00535-018-1515-6.
  • Fukuda H, Miura Y, Hayashi Y, et al. Linked color imaging technology facilitates early detection of flat gastric cancers. Clin J Gastroenterol. 2015;8(6):385–389. doi:10.1007/s12328-015-0612-9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.